(NASDAQ: MREO) Mereo Biopharma Group's forecast annual revenue growth rate of 466.73% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 107.7%, and it is also forecast to beat the US market's average forecast revenue growth rate of 26.15%.
Mereo Biopharma Group's revenue in 2025 is $500,000.On average, 9 Wall Street analysts forecast MREO's revenue for 2025 to be $22,612,439,668, with the lowest MREO revenue forecast at $0, and the highest MREO revenue forecast at $66,403,060,624. On average, 9 Wall Street analysts forecast MREO's revenue for 2026 to be $38,928,620,279, with the lowest MREO revenue forecast at $0, and the highest MREO revenue forecast at $77,679,052,051.
In 2027, MREO is forecast to generate $76,807,996,628 in revenue, with the lowest revenue forecast at $6,548,427,614 and the highest revenue forecast at $115,265,690,140.